In prostate cancer (PCa), the use of new radiopharmaceuticals has improved the accuracy of
diagnosis and staging, refined surveillance strategies, and introduced specific and …

Breast cancer is one of the most common malignancies in women, with high morbidity and
mortality rates. In breast cancer, the use of novel radiopharmaceuticals in nuclear medicine …

Objective The aim of this study was (1) to investigate the application of texture analysis of
choline PET/CT images in prostate cancer (PCa) patients and (2) to propose a machine …

Novel radiopharmaceuticals for PET are being evaluated for the diagnosis of biochemical
recurrence (BCR) of prostate cancer (PC). We compared the gastrin-releasing peptide …

Targeting tumor-expressed receptors using selective molecules for diagnostic, therapeutic,
or both diagnostic and therapeutic (theragnostic) purposes is a promising approach in …

Simple Summary Prostate cancer (PCa) relapse occurs in up to 50% of patients after radical
treatment. Once PCa recurrence is detected, a precise identification of the number and sites …

68Ga-RM2 targets gastrin-releasing peptide receptors (GRPRs), which are overexpressed
in prostate cancer (PC). Here, we compared preoperative 68Ga-RM2 PET to postsurgery …

Despite advancements in pancreatic cancer treatment, it remains one of the most lethal
malignancies with extremely poor diagnosis and prognosis. Herein, we demonstrated the …

Radiopharmaceuticals involve the local delivery of radionuclides to targeted lesions for the
diagnosis and treatment of multiple diseases. Radiopharmaceutical therapy, which directly …

For prostate cancer (PCa) biochemical recurrence (BCR), the primarily suggested imaging
technique by the European Association of Urology (EAU) guidelines is prostate-specific …